ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Serum Institute of IndiaSubscribe to Serum Institute of India

COVID-19 and IPR Waiver

The Government of India is seeking an intellectual property rights waiver under Sections 1 (copyright and related rights), 4 (industrial designs), 5 (patents), and 7 (protection of undisclosed information) of the Agreement on Trade-Related Aspects of Intellectual Property Rights. Seeking an IPR waiver is based on the presumption that it will allow more firms to manufacture vaccines and medicines, thereby enhancing their availability at a cheaper price. However, IPR waivers for COVID-19 vaccines and medicines are unlikely to make any difference. A more effective approach is to use compulsory licences, and reduce tariffs and non-tariff measures.

 

Why India’s Vaccine Companies Are Profiteering in the Pandemic

The crisis of COVID-19 vaccines in India is a consequence of government policies dating back decades. Private foundations led by the Bill and Melinda Gates Foundation have engineered a shift in research and manufacture of essential technologies such as vaccines to private biotech labs and factories. Companies such as the Serum Institute of India and Bharat Biotech can dictate terms and prices of vaccines developed with public support because the closure of public vaccine manufacturing units over a decade ago has left the government at the mercy of the private sector.

 

Back to Top